(Q33977969)

30 July 2017

title

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies (English)

1 reference

30 July 2017

1 reference

1 reference

10

M J Ratain

1 reference

30 July 2017

E E W Cohen

1

1 reference

30 July 2017

M R Sharma

2

1 reference

30 July 2017

L Janisch

3

1 reference

30 July 2017

M Llobrera

4

1 reference

30 July 2017

L House

5

1 reference

30 July 2017

K Wu

6

1 reference

30 July 2017

J Ramirez

7

1 reference

30 July 2017

G F Fleming

8

1 reference

30 July 2017

W M Stadler

9

1 reference

30 July 2017

publication date

23 March 2011

1 reference

European Journal of Cancer

30 July 2017

published in

1 reference

30 July 2017

volume

47

1 reference

30 July 2017

issue

10

1 reference

30 July 2017

page(s)

1484-1489

1 reference

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

Rapamycin: something old, something new, sometimes borrowed and now renewed

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

Sirolimus: the evidence for clinical pharmacokinetic monitoring.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

From beach to bedside: history of the development of sirolimus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

Clinical pharmacokinetics of sirolimus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

mTOR: the mammalian target of replication

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin).

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116678

Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21439817

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.EJCA.2011.02.017

1 reference

30 July 2017

1 reference

30 July 2017

1 reference